Reflex high-risk human papillomavirus DNA testing (Hybrid Capture 2) of bloody ThinPrep specimens with atypical squamous cells of undetermined significance interpretation: Does pretreatment with acetic acid affect test performance?

Cancer

Volumn 105, Issue 6, 2005, Pages 452-456

  Feng, Jining ^a,b   Husain, Mujtaba ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical squamous cells of undetermined significance; Bloody specimen; Glacial acetic acid treatment; Human papillomavirus test; Hybrid Capture 2; ThinPrep Papanicolaou test

Indexed keywords

ACETIC ACID; VIRUS DNA;

ACID PRETREATMENT; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; ATYPICAL SQUAMOUS CELL OF UNDETERMINED SIGNIFICANCE; BLOOD; BLOODY SAMPLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC KIT; DNA DETERMINATION; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PERFORMANCE; PILOT STUDY; PRIORITY JOURNAL; SAMPLE; TECHNIQUE; UTERINE CERVIX CARCINOMA; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

ACETIC ACIDS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PILOT PROJECTS; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 30344444779     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21349     Document Type: Article

References (14)

1. Hutchinson ML, Isenstein LM, Goodman A, et al. Homogeneous sampling accounts for the increased diagnostic accuracy using the ThinPrep Processor. Am J Clin Pathol. 1994;101:215-219.
2. Roberts JM, Gurley AM, Thurloe JK, Bowditch R, Laverty CR. Evaluation of the ThinPrep Pap test as an adjunct to the conventional Pap smear. Med J Aust. 1997;167:466-469.
3. Papillo JL, Zarka MA, St John TL. Evaluation of the ThinPrep Pap test in clinical practice. A seven-month, 16,314-case experience in northern Vermont. Acta Cytol. 1998;42:203-208.
4. Bolick DR, Hellman DJ. Laboratory implementation and efficacy assessment of the ThinPrep cervical cancer screening system. Acta Cytol. 1998;42:209-213.
5. Weintraub J, Morabia A. Efficacy of a liquid-based thin layer method for cervical cancer screening in a population with a low incidence of cervical cancer. Diagn Cytopathol. 2000;22:52-59.
6. The ASCUS-LSIL Triage study (ALTS) group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383-1392.
7. Wright TC Jr., Cox JT. Clinical uses of human papillomavirus (HPV) DNA testing. American Society for Colposcopy and Cervical Pathology, 2004. Available from URL: http://www.cme.asccp.org [accessed July 14, 2005].
8. Bentz JS, Rowe LR, Gopez EV, Marshall CJ. The unsatisfactory ThinPrep®: missed opportunity for disease detection? Am J Clin Pathol. 2002;117:457-463.
9. Islam S, West AM, Saboorian MH, Ashfaq R. Reprocessing unsatisfactory ThinPrep Papanicolaou test specimens increases sample adequacy and detection of significant cervicovaginal lesions. Cancer (Cancer Cytopathol). 2004;102:67-73.
10. ARUP, Institute for Clinical and Experimental Pathology, LLC. CytoLyt®/glacial acid wash solution protocol. Sandy, UT: 2002.
11. ThinPrep 2000 Operator's manual. 2002; sec. 8.24.
12. Hecht SA, Swinehart W, Linder J. Comparison of methods for reprocessing bloody gynecological specimens in Preserv-Cyt® solution [abstract 25]. Acta Cytol. 2004;48:681.
13. Agoff SN, Dean T, Nixon BK, Ingalls-Severn K, Rinker L, Grieco VS. The efficacy of reprocessing unsatisfactory cervicovaginal ThinPrep specimens with and without glacial acetic acid: effect on Hybrid Capture II human papillomavirus testing and clinical follow-up. Am J Clin Pathol. 2002;118:727-732.
14. Rowe LR, Bentz JS. A simple method to determine the need for glacial acetic acid treatment of bloody ThinPrep Pap tests before slide processing. Diagn Cytopathol. 2004;31:321-325.